Newsmeme!
Discover News you didn't know existed
Immunotherapy
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
J&J buys US$1-billion stake in Alzheimer drug maker
Published July 4, 2009, 9:42 am, National Post
Johnson and Johnson is take over most of Elan Corp. Alzheimer's research and invest US$1-billion in new Elan equity in exchange for an 18.4% stake in the Irish drugmaker, the companies said on Thursday.
Scratching the surface of canine allergies
Published July 4, 2009, 5:36 am, Carteret County News-Times
(ARA) - Most people consider their dog to be more than just a pet. Dogs are true members of the family. So when your dog is itching uncontrollably, it is frustrating not to know what's wrong. Once owners rule out the possibility of fleas, they are often left with questions unanswered.
J&J to acquire Alzheimer's Immunotherapy Programme from Elan
Published July 3, 2009, 10:48 pm, PharmaBiz
Johnson & Johnson and Elan Corporation plc announced a definitive agreement whereby J&J will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Programme (AIP Programme), through a newly formed company.
Johnson & Johnson buy $1.5 billion stake in Irish biotech Elan
Published July 3, 2009, 5:08 pm, Irish Central
Johnson & Johnson has bought all of Elan’s Assets in their Alzheimer's Immunotherapy Program for $1 billion and will receive 18.4 per cent of company shares as part of the deal.
Construction begins on Allergy Associates building in Onalaska
Published July 3, 2009, 9:05 am, Onalaska Holmen Courier-Life
Allergy Associates of La Crosse broke ground Tuesday on its new 10,000-square-foot patient care facility in Onalaska.
Johnson & Johnson pays $1B for Elan stake
Published July 3, 2009, 7:45 am, Daily Record
Johnson & Johnson, making a big jump into the risky but potentially lucrative field of Alzheimer's disease, is taking a major stake in Irish biopharmaceutical company Elan Corp., investing up to $1.5 billion initially.
Johnson & Johnson acquires $1.5B stake in Elan
Published July 3, 2009, 4:48 am, The Star-Ledger
Johnson & Johnson plunged into the high-stakes race to find new medicines for Alzheimer's disease yesterday by acquiring a $1.5 billion stake in Irish biotech Elan. The investment gives the New Brunswick-based health care giant an 18.4 percent share in...
My Pharmiweb.com
Published July 3, 2009, 3:19 am, PharmiWeb
New Brunswick, N.J., and Dublin, Ireland, July 2, 2009 – Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program (AIP Program), through a newly formed company.
Alzheimer drug access key to deal with Élan
Published July 3, 2009, 1:35 am, Toronto Star
Johnson & Johnson, the health-care giant, will pay $1 billion (U.S.) to the Irish biotechnology company Élan to gain access to its Alzheimer's disease treatment drugs, the companies said yesterday.
Research and Markets: Examine the Fundamental Science and the Latest Developments in Carbohydrate-Based Vaccines
Published July 3, 2009, 1:22 am, Business Wire via Yahoo! Finance
DUBLIN----Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "Carbohydrate-Based Vaccines and Immunotherapies" to their offering.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |